Company intelligence / Profile preview

Fugeia

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Developed novel wheat bran-derived dietary fibers with demonstrated benefits for gut health; products were commercialized via partnerships with major food companies prior to acquisition by Cargill in 2017[1].

Modalities: Functional food ingredientsnutrition technologies
Industry: Food & Nutrition

Drug pipeline

1 asset

wheat bran extract

Commercial

Indications: Digestive health, Gastrointestinal disorders

Partnerships

Partnered with global food companies to commercialize its wheat bran fiber technology prior to acquisition by Cargill[1]

Beyond the preview

Go deeper on Fugeia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fugeia.

Explore the full profile